Pharmacoeconomic Analysis of Drug Therapy of Chronic Obstructive Pulmonary Disease: Umeclidinium Bromide/Vilanterol Compared with other Combinations of Long-Acting ß-Antagonists and Anticholinergics
The article presents the results of pharmacoeconomic study of umeclidinium bromide/vilanterol compared with tiotropium bromide/olodaterol and glycopyrronium bromide/vilanterol for the treatment of patients with chronic obstructive pulmonary disease (COPD). It was found that the use of umeclidinium bromide/vilanterol reduces the cost of therapy (26 and 29% respectively) and direct medical costs (23 and 25% respectively), and also increases the effectiveness in respect of the criteria that characterise external respiration in patients with obstructive pulmonary diseases based on the measurement of volume that has been exhaled at the end of the first second of forced expiration (FEV1). It is also the most convenient and simple in use and maintenance.